Prostaglandin E 2 synthase (mPGES-1), the enzyme which catalyzes the synthesis of PGE 2 , is induced during the inflammatory response. For this reason, mPGES-1 could be a potential therapeutic target. A high-throughput screening assay was developed to identify potential inhibitors of mPGES-1. The assay consisted of a 30-s mPGES-1 enzymatic reaction followed by the detection of PGE 2 by enzyme immunoassay (EIA). The enzymatic reaction was performed in a batch mode because the instability of the substrate (10 min) limited the number of plates assayed within a working day. The detection of the product by EIA was performed on 3 instruments requiring 14 different steps for complete automation. The authors describe here the optimization and implementation of a 2-part assay on a Thermo CRS robotic system. More than 315,000 compounds were tested, and a hit rate of 0.84% was obtained for this assay. Although the entire assay required multiple steps, the assay was successfully miniaturized and automated for a high-throughput screening campaign. (Journal of Biomolecular Screening 2005:599-605) 
INTRODUCTION
P ROSTAGLANDINS (PG) ARE MAJOR biological mediators. 1 Their production is initiated by phospholipase A 2 , which releases arachidonic acid (AA) from the phospholipid bilayer. 2 Conversion of AA to prostaglandin H 2 (PGH 2 ) is catalyzed by cyclooxygenase (COX)-1 or COX-2, and this unstable intermediate is then rapidly converted by various synthases into other prostaglandins. 3 The production of PGE 2 by PGE 2 synthase (PGES) is believed to play a role in multiple physiological processes including reproduction, 4 bone metabolism, 5 and kidney function, 6 as well as in a number of pathologies such as inflammation, 5,7-9 pain, 10 fever, 11, 12 tumorigenesis, [13] [14] [15] and Alzheimer's disease. 16 PGES exist in 2 forms, cytosolic (cPGES) and membraneassociated (mPGES). cPGES is constitutively expressed and promotes immediate PGE 2 production via constitutive COX-1 for the maintenance of cellular homeostasis. 17 mPGES, more specifically mPGES-1, is inducible and was shown through cotransfection studies to predominantly couple to the inducible COX-2. 18 An-other mPGES, mPGES-2, was identified and differs from mPGES-1 in terms of primary structure, thiol requirement, and tissue distribution. 19 Although there is limited influence on cPGES and mPGES-2 by proinflammatory stimuli, there is evidence in many biological systems that mPGES-1 is upregulated under such conditions. 7, 8, 18, [20] [21] [22] The concomitant induction of mPGES-1 and COX-2, along with their functional coupling, accounts for the predominant production of PGE 2 during inflammation. Therefore, the inducible form mPGES-1 may provide a novel therapeutic target for inflammation and other PGE 2 -mediated pathologies downstream of COX-2.
The mPGES-1 activity assay published by Ouellet et al. was developed in 96-well plates using PGH 2 as substrate. 23 The enzyme is supplemented with glutathione (GSH), and the reaction is terminated at a set time to obtain about 50% substrate conversion. However, one limiting factor in this assay is the instability of the substrate. PGH 2 nonenzymatically degrades to PGE 2 and PGD 2 , with a half-life of about 10 min at room temperature (RT). 24 Thus, to enable a high-throughput screening (HTS) campaign for mPGES-1, the substrate would require cooling to extend the half-life. 22, 23 Moreover, to account for the nonenzymatic degradation of unreacted PGH 2 , the enzymatic reaction is terminated by the addition of SnCl 2 , which converts PGH 2 to PGF 2α . 25 Measurement of PGE 2 can be performed by an enzyme immunoassay (EIA). This type of assay requires many steps such as large sample dilution, long incubation periods, and washing steps, all of which are not ideal for HTS. Nonetheless, here we describe the miniaturization and implementation of a 384-well format mPGES-1 enzymatic assay and PGE 2 EIA.
MATERIALS AND METHODS
PGH 2 was obtained from BIOMOL (Plymouth Meeting, PA) and the PGE 2 EIA kit from Assay Designs (Ann Arbor, MI). The 384-well EIA plates (clear polystyrene, square flat-bottom well; Greiner, Austria) coated with goat antimouse antibody were obtained from NoAb/BioDiscoveries (Toronto, Canada). A Biomek FX (Beckman Coulter, Fullerton, CA) equipped with a 384-multichannel head was integrated on a Thermo CRS robotic system (Burlington, Canada) to execute, except where noted, all pipetting steps.
mPGES-1 enzymatic reaction
The recombinant human mPGES-1 enzyme was expressed in baculovirus-Sf9 cell system as previously described by Ouellet et al. 23 The microsomal fraction was isolated and 25 µL of 1 µg/mL mPGES-1 (1×) (100 mM KHPO 4 buffer pH 7.0 supplemented with 2 mM EDTA and 2.5 mM reduced GSH) was added to each well of a Costar polypropylene 384-well plate (Corning, Corning, NY). An equivalent volume of negative control (Mock) was added at 1 µg/mL which consisted of a microsomal fraction obtained from Sf9 cells infected with a baculovirus containing an empty vector. Compounds were screened at a final concentration of 10 µM and an equal amount (1.2 µL) of DMSO was added to each control well. Compounds were incubated with the enzyme for 15 min at RT before the addition of 1 µL cold PGH 2 (1 µM final) to initiate the enzyme reaction. After 30 s, the reaction was stopped by adding 12.5 µL of 3.3 mg/mL SnCl 2 solution in 1 N HCl to convert the remaining PGH 2 to PGF 2α . 25 The enzymatic reaction was carried out in batches of 7 assay plates. On average, 4 batches were processed during 1 screening day. Before performing the EIA on the robotic system, reaction plates were manually lidded to avoid evaporation from the assay wells.
Enzyme immunoassay for PGE 2 PGE 2 was measured by EIA, with some modifications to the supplier's protocol. Controls and samples were diluted 625-fold in EIA buffer containing 0.01% bovine serum albumin (BSA), from which 20 µL was transferred to a 384-well EIA plate coated with a goat antimouse antibody. Then, 10 µL of anti-PGE 2 mouse antibody (Assay Designs kit) and 10 µL of the alkaline phosphataselinked-PGE 2 tracer (Assay Designs kit) were added to each well. Plates were incubated 3 h at RT without shaking. Samples were washed 3 times with 50 µL of wash buffer (Assay Designs kit) on an Embla 384-well plate washer (model 12386, Molecular Devices, Sunnyvale, CA). Finally, 40 µL of p-nitrophenylphosphate (pNpp; Assay Designs kit) was dispensed into each well using a multidrop 8-channel dispenser (type 832, Labsystems, Waltham, MA). Following 3-or 4-h incubation at RT without shaking, plates were read at 405 nm in a Biotek FL600 plate reader (Winooski, VT).
Calculations
All calculations are based on the optical density (OD) readings:
RESULTS AND DISCUSSION

Comparison of 96-and 384-well assay conditions
The mPGES-1 enzymatic reaction and the detection of PGE 2 in a 96-well format were previously described 23, 26 and served as the starting point to develop a 384-well assay amenable to robotic screening ( Table 1 ). The 1st issue in the optimization of the assay was the pipetting accuracy and precision of the Biomek FX 384multichannel head. Several trials of aspirate/dispense parameters were examined to identify the lowest DMSO volume that could be pipetted with a coefficient of variance (CV) less than 10% across 1 plate. The accuracy was assessed by comparing the fluorescence of a rhodamine B solution pipetted by the Biomek FX with the one obtained using a calibrated manual pipettor. The accuracy of this volume was important, as it would affect both the DMSO and compound concentration in the assay. The determined volume was 1.2 µL and corresponded to 4.4% DMSO in the 384-well assay. In comparison with the 1% DMSO in 96-well format, higher concentration of DMSO gave similar mPGES-1 specific activity ( Fig. 1 , Table 1 ).
Another encumbering factor for the determination of mPGES-1 activity was the instability of the substrate. At RT and neutral pH, PGH 2 is highly unstable and predominantly degrades nonenzymatically into PGE 2 , the prostaglandin of interest. 24 The half-life of PGH 2 at RT is 10 min but when kept at 0°C, the half-life is extended to 30 min. 22, 23 In light of this constraint, the enzymatic assay could not be run in a continuous manner. Instead, a batch process was devised on the robotic system permitting the run of 7 assay plates per batch, in which the addition of the substrate was completed within 15 min. PGH 2 was always prepared fresh and kept at 4°C on the cooling Automated Labware Positioner (ALP) of the Biomek FX. One batch of plates was run in about 2 h, and the throughput, including the EIA, was 28 plates per day. The mPGES-1 enzymatic reaction is quenched by the addition of SnCl 2 to convert the remaining substrate to PGF 2α , 25 which is marginally detected by the EIA antibody (0.7% cross-reactivity). When run in the 96-well format, reaction plates were centrifuged because the presence of SnCl 2 in the solution was considered to interfere with the EIA. Another concern was the acidification of the samples by the addition of 1 N HCl, which was then neutralized with NaOH. These steps were examined and showed no interference in PGE 2 detection (data not shown). Thus, the EIA in the 384well screen was executed without centrifugation or neutralization.
To minimize costs, the addition of substrate and SnCl 2 were performed with the same tips used to add the compounds in the previous step. Between the compound and substrate/SnCl 2 additions, tips were washed 4 times with water in the tip-washing ALP of the Biomek FX and then 3 times in a trough containing 100% EtOH. Tips were left to dry for at least 15 min before they were reutilized. No impact was observed on assay quality.
In regard to the detection of PGE 2 by EIA, the 1st issue encountered in miniaturizing the assay was the transfer of the reaction samples into EIA plates. The samples required a 625-fold (2 × 25fold) dilution in assay buffer containing BSA. The dilution was achieved by programming 8 pipetting steps on the Biomek FX because the maximum volume of the tips was 30 µL and the working volume of the plate wells was no more than 100 µL. In addition, during these pipetting steps, the presence of BSA in the assay buffer had the propensity to generate air bubbles resulting in inaccurate transfer. This issue was resolved by evaluating EIA buffers with different BSA concentrations. At the lowest BSA concentration, pipetting was accurate and no effect was noted on the detection of PGE 2 (Fig. 2) . Therefore, we selected 0.01% BSA as the working concentration in the screening assay (a 10-fold reduction compared to supplier's kit).
The next step in the EIA process was the incubation of samples with the PGE 2 antibody and tracer. The protocol from the manufacturer suggests shaking the EIA plate for 2 h. Unfortunately, the plate shaker on our robotic system could only accommodate 4 plates at a time. This limitation prevented the continuous processing of the assay plates and restricted the throughput. Consequently, the assay was performed without any shaking and this change was compensated by extending the incubation to 3 h ( pipetting step, addition of EIA stop solution was omitted from the procedure. The impact on the detection of PGE 2 was minimal because the plates were read immediately after the incubation period.
Robotic assay validation
Before initiating the HTS campaign, an experiment was conducted to verify the reliability of the robotic assay. The validation was accomplished by running the enzymatic assay with 10 known mPGES-1 inhibitors uniformly distributed across a 384-well plate in a unique pattern (Fig. 3A) . Compounds were tested in quadruplicate at a final concentration of 10 µM, and results were analyzed graphically using an in-house Excel spreadsheet that associated color to residual activity ranges. Through this analysis, each unique pattern was clearly identified (Fig. 3B) . The positive controls with maximal synthase activity (1×) had a CV of 5% to 10%. Based on 3-fold standard deviation (3× STD) of these controls, 70 out of 80 wells containing compound confirmed their inhibitory activity on the enzyme, resulting in a confirmation rate of 87.5% Compound #7 8
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for this validation experiment. The experiment was run 2 times with similar results. False-positive wells were identified and represented 0.6% of the wells that received DMSO only. In light of these results, an HTS campaign was performed on a partial set of the Merck collection.
Results of the HTS campaign
More than 315,000 compounds from our sample collection were screened against mPGES-1 at 10 µM in a 384-well format. The assay signal for positive and negative controls was constant throughout the screen with CVs lower than 10% (Fig. 4) . Average OD values for plates 816 to 1039 are slightly higher because the incubation time with the substrate was increased to 4 h. The reason for that change was to increase the signal (Fig. 4A) after the observation of a decreasing OD window in previous plates. In addition, the high OD values observed toward the end of the campaign (~plate 1000) was attributed to a robotic malfunction and consequently to a longer development time. Despite these changes in signal, the reconfirmation rate remained constant throughout the screen.
To maximize the number of compounds per plate, the assay did not include a PGE 2 standard curve. For this reason, the PGE 2 assay window and Z′ factors were not calculated and the percentage of inhibition for each compound was based on raw OD data. The false-positive rate was 0.2% based on wells containing DMSO. The frequency distribution graph was plotted using the residual ac-tivity from all samples and demonstrated a tight, bell-shaped curve grouped at 100% residual activity (Fig. 5 ). For this campaign, hit selection was based on 3-fold STD of the 100% controls (residual activity lower than 81.1%) and on B-scores 27 higher than 5. Bscores are a statistical method which selects hits based on raw data and corrects for positional effects. In total, close to 2600 compounds (upper right corner in Fig. 6 ) were identified as potential inhibitors of mPGES-1 which corresponds to a hit rate of 0.84%. These compounds were titrated in 384-well plates and 76% recon- firmed with an IC50 less than 10 µΜ (data not shown). Structureassociated relationship was followed up on 12 different chemical classes.
CONCLUSION
Despite all the limitations of the mPGES-1 enzymatic reaction and PGE 2 EIA, we were successful in miniaturizing and automating the mPGES-1 assay from a 96-to a 384-well format. We have conducted an HTS campaign and obtained a hit rate of 0.84%. Reconfirmation of these potential mPGES-1 inhibitors was greater than 75%. Small-molecule screening has enabled us to identify 12 novel chemical classes that are being further pursued. BIND identifier. One BIND identifier (www.bind.ca) is associated with this article: 316088. For more information about the Society for Biomolecular Screening, visit www.sbsonline.org.
